Lexeo Therapeutics (NASDAQ:LXEO) COO Sells $19,302.40 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) COO Jose Manuel Otero sold 3,016 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $6.40, for a total transaction of $19,302.40. Following the completion of the transaction, the chief operating officer directly owned 125,460 shares of the company’s stock, valued at $802,944. This represents a 2.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Lexeo Therapeutics Stock Performance

NASDAQ LXEO opened at $6.29 on Monday. The firm’s 50 day moving average price is $8.30 and its two-hundred day moving average price is $7.67. The stock has a market cap of $459.11 million, a price-to-earnings ratio of -2.33 and a beta of 1.79. Lexeo Therapeutics, Inc. has a twelve month low of $1.45 and a twelve month high of $10.99.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LXEO. HC Wainwright reduced their price objective on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Oppenheimer reissued an “outperform” rating and issued a $20.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. Raymond James Financial assumed coverage on shares of Lexeo Therapeutics in a report on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Lexeo Therapeutics in a research note on Monday, December 1st. They issued an “overweight” rating and a $19.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Hedge Funds Weigh In On Lexeo Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. bought a new position in Lexeo Therapeutics during the fourth quarter valued at approximately $4,598,000. Vestal Point Capital LP increased its stake in shares of Lexeo Therapeutics by 37.7% during the 4th quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after purchasing an additional 1,225,000 shares during the last quarter. Virtus Investment Advisers LLC bought a new position in shares of Lexeo Therapeutics during the 4th quarter valued at $270,000. Wellington Management Group LLP acquired a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at $826,000. Finally, Susquehanna Portfolio Strategies LLC lifted its stake in shares of Lexeo Therapeutics by 14.4% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 26,205 shares of the company’s stock valued at $260,000 after purchasing an additional 3,296 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.